Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s Latest Updates


Dallas, Texas 04/01/2014 (FINANCIALSTRENDS) – Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has been one of the leading pharmaceutical company which are engaged in developing drugs for treating gastrointestinal GI. The product also treats other disorders as well as other diseases.  The product candidate for this company is plecanatide.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has been using this product to develop an excellent user line for patients suffering from a range of GI disorder. These include patients who have been suffering from conditions such as long term constipation as well as those patients who have been troubled by constipation as well as irritable bowel movement.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) holds market capital of $496.84 million. The company has a 52-week trading high of $7.44 and trading low of $3.83. The average volume trades for the company have been to the tune of 1.50 million. The EPS is -0.74. Outstanding shares held are 93.57 million.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has also reliably used its lead candidate to offer relief to patients suffering from IBS-C. Currently, the company is also involved in the development of SP-333, which is second generation GC-C receptor. These are agonistic in nature and are used for the treatment of gastrointestinal inflammatory diseases. These are also useful in treating conditions which are reacting to ulcer.

It is also to be noted that the given pharmaceutical ingredients which part of the Active Pharmaceutical ingredients are also used to finally formulate drug products. It has also been involved in third party contractual work across the technologies it offers. For the past couple of years, the company has been producing synthetic hexadecapeptides as well. These drugs are given to mimic such of the actions as those performed by hormone uroguanylin. Besides, it is used for treating conditions of constipation using the synthetics as well. Additionally, Plecanatide is also considered to be a GC-C receptor.